aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Rating of "Hold" by Analysts

Key Points

• aTyr Pharma, Inc. (NASDAQ:ATYR) has received an average analyst rating of "Hold", with six analysts recommending a hold and one a buy.
• The company's stock price has significantly decreased, with shares down 9.3% and currently priced at $0.72, well below its 12-month high of $7.29.
• Significant institutional interest has been noted, with approximately 61.72% of the stock owned by hedge funds and other institutional investors.

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) have earned an average rating of "Hold" from the seven research firms that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $23.25.

ATYR has been the topic of a number of analyst reports. Leerink Partners reaffirmed a "market perform" rating on shares of aTyr Pharma in a report on Monday, September 15th. Cantor Fitzgerald downgraded aTyr Pharma from an "overweight" rating to a "neutral" rating in a research note on Monday, September 15th. Jefferies Financial Group boosted their target price on aTyr Pharma from $9.00 to $17.00 and gave the stock a "buy" rating in a research note on Friday, August 22nd. Wall Street Zen cut aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Finally, Leerink Partnrs cut aTyr Pharma from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 15th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATYR. Bank of America Corp DE purchased a new position in aTyr Pharma in the fourth quarter valued at about $330,000. Millennium Management LLC purchased a new position in aTyr Pharma in the fourth quarter valued at approximately $1,332,000. Two Sigma Investments LP purchased a new position in aTyr Pharma in the fourth quarter valued at approximately $78,000. Two Sigma Advisers LP purchased a new position in aTyr Pharma in the fourth quarter valued at approximately $44,000. Finally, Squarepoint Ops LLC purchased a new position in aTyr Pharma in the fourth quarter valued at approximately $96,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

aTyr Pharma Stock Down 9.3%

Shares of NASDAQ:ATYR opened at $0.72 on Wednesday. The stock has a market cap of $70.69 million, a price-to-earnings ratio of -0.90 and a beta of 1.01. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. aTyr Pharma has a 12-month low of $0.70 and a 12-month high of $7.29. The business's 50 day moving average is $4.27 and its 200 day moving average is $4.17.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04). On average, sell-side analysts forecast that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.